We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed at $317.27 in the latest trading session, marking a -1.8% move from the prior day. This change lagged the S&P 500's 1.05% gain on the day. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq added 9.7%.
Coming into today, shares of the drugmaker had gained 12.96% in the past month. In that same time, the Medical sector lost 0.85%, while the S&P 500 gained 6.27%.
Investors will be hoping for strength from Vertex Pharmaceuticals as it approaches its next earnings release, which is expected to be February 7, 2023. On that day, Vertex Pharmaceuticals is projected to report earnings of $3.53 per share, which would represent year-over-year growth of 4.75%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.29 billion, up 10.55% from the year-ago period.
Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.99% lower within the past month. Vertex Pharmaceuticals is currently a Zacks Rank #3 (Hold).
Digging into valuation, Vertex Pharmaceuticals currently has a Forward P/E ratio of 20.93. For comparison, its industry has an average Forward P/E of 20.93, which means Vertex Pharmaceuticals is trading at a no noticeable deviation to the group.
Investors should also note that VRTX has a PEG ratio of 1.97 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.63 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 91, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VRTX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Vertex Pharmaceuticals (VRTX - Free Report) closed at $317.27 in the latest trading session, marking a -1.8% move from the prior day. This change lagged the S&P 500's 1.05% gain on the day. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq added 9.7%.
Coming into today, shares of the drugmaker had gained 12.96% in the past month. In that same time, the Medical sector lost 0.85%, while the S&P 500 gained 6.27%.
Investors will be hoping for strength from Vertex Pharmaceuticals as it approaches its next earnings release, which is expected to be February 7, 2023. On that day, Vertex Pharmaceuticals is projected to report earnings of $3.53 per share, which would represent year-over-year growth of 4.75%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.29 billion, up 10.55% from the year-ago period.
Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.99% lower within the past month. Vertex Pharmaceuticals is currently a Zacks Rank #3 (Hold).
Digging into valuation, Vertex Pharmaceuticals currently has a Forward P/E ratio of 20.93. For comparison, its industry has an average Forward P/E of 20.93, which means Vertex Pharmaceuticals is trading at a no noticeable deviation to the group.
Investors should also note that VRTX has a PEG ratio of 1.97 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.63 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 91, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VRTX in the coming trading sessions, be sure to utilize Zacks.com.